Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
P/S ratio for Zealand Pharma A/S (ZEAL.CO)
P/S ratio as of 2023: 61.61
According to Zealand Pharma A/S's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 61.61. At the end of 2022 the company had a P/S ratio of 89.48.
P/S ratio history for Zealand Pharma A/S from 2007 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 61.61 |
| 2022 | 89.48 |
| 2021 | 21.26 |
| 2020 | 23.96 |
| 2019 | 192.51 |
| 2018 | 67.08 |
| 2017 | 17.66 |
| 2016 | 11.03 |
| 2015 | 18.61 |
| 2014 | 12.21 |
| 2013 | 203.09 |
| 2012 | 8.70 |
| 2011 | 8.95 |
| 2010 | 14.58 |
| 2009 | 60.06 |
| 2008 | 27.03 |
| 2007 | 25.38 |